Aehr Test Systems Is Up 333% This Year. Insiders Are Cashing Out.

The insider selling

The cluster of insider sales is notable for both its breadth and its timing. Director Rhea J. Posedel, the company's co-founder, sold 30,000 shares on April 9 at $70.00 per share for $2.1 million. Director Laura Oliphant sold 3,000 shares the same day at $68.36. VP Alistair Sporck sold 2,000 shares on April 10 at $67.36 (to cover tax withholding obligations related to equity award vesting, per the filing). Director Fariba Danesh sold 10,500 shares across April 10 and April 13 at prices around $70 to $71.50. COO Adil Engineer and CTO Don Richmond also sold shares in the same window.

In total, insiders have sold roughly 90,880 shares worth approximately $5.6 million in the last three months, according to SEC filings compiled by American Banking News. Insiders still own 6.80 percent of the company's outstanding shares.

To be sure, insider selling after a 333 percent rally is not inherently alarming: executives with concentrated equity positions routinely diversify, and some of the transactions were explicitly tied to tax withholding on vesting awards. But the sheer number of participants (at least six named insiders in a two-week span) and the scale of the dispositions are worth noting, particularly given where the stock now trades relative to analyst expectations.

The valuation disconnect

The gap between Aehr's current share price and Wall Street's consensus target is unusually wide, and it runs in the wrong direction. The median analyst price target sits at approximately $62, which implies roughly 29 percent downside from Wednesday's close. The high target among covering analysts is $68, still 22 percent below the current price.

Craig Hallum upgraded shares to Buy on April 8 with a $68 price target. William Blair raised its rating to Outperform in early March. Lake Street Capital reiterated a Buy rating. But even the most bullish published target on the Street is below where the stock currently trades. The market is pricing in a growth trajectory that analysts have not yet endorsed.

What drove the rally

The 333 percent year-to-date gain is rooted in a genuine business inflection. Aehr's core product line, the FOX family of wafer-level burn-in systems, has found new demand from AI chip manufacturers who need to stress-test advanced processors before deployment. The company reported $37.2 million in bookings during its fiscal third quarter (ended February 27, 2026), a figure that dwarfed the $10.3 million in revenue it recorded in the same period. The effective backlog reached $50.9 million.

The bookings surge reflects several catalysts that emerged over the past year: a $14 million order from a lead AI processor customer in February 2026, a new silicon photonics customer win for hyperscale data center optical interconnects in March, and the successful launch of the Sonoma family of ultra-high-power burn-in systems for AI accelerators (acquired through the Incal Technology deal). CEO Gayn Erickson noted that Aehr is "the only company on the market that offers both a WLBI and a PPBI system for both qualification and production burn-in of AI processors."

The company reaffirmed guidance for $25 million to $30 million in second-half fiscal 2026 revenue and said it expects to return to adjusted profitability in the current quarter.

The fundamentals underneath

The enthusiasm is real. The financials are still catching up. Aehr posted a non-GAAP loss of $0.05 per share in fiscal Q3, beating the consensus estimate of a $0.07 loss by $0.02. But revenue of $10.3 million missed the average analyst target by roughly $540,000. Net margins remain deeply negative at approximately negative 31 percent. Full-year fiscal 2025 revenue was $59 million, down from $66.2 million the prior year, per the company's annual results.

The company had $26.5 million in cash as of May 2025 and used $7.4 million in operating cash flow during fiscal 2025. At a market capitalization of $2.8 billion, the stock trades at roughly 47 times the high end of its second-half revenue guidance (annualized), a valuation that assumes the bookings backlog converts to revenue on schedule and that the AI burn-in opportunity scales rapidly from here.

Institutional investors appear to be taking a mixed view. Vanguard Group increased its stake by 2.9 percent in Q3 2025. Wellington Management boosted its position by 33.4 percent in the same quarter. But Baillie Gifford, the Edinburgh-based investment firm, cut its stake by 15.7 percent in Q4, selling nearly 240,000 shares.

The question the market hasn't answered

Aehr's bull case is straightforward: every major AI chip needs to be tested and burned in before deployment, the company has a first-mover advantage in wafer-level burn-in for AI processors, and the $50.9 million backlog provides near-term revenue visibility. The bear case is equally direct: the stock has already priced in years of growth, insiders are selling into the rally, every covering analyst's target is below the current price, and the company is still losing money on a GAAP basis.

The stock's pause on Wednesday resolved nothing. Only time will tell whether the backlog converts at the pace the market expects, but the insiders who know the business best appear to have made their own assessment.